The specialty can serve as a “valuable asset” in the rollout, including gauging drug efficacy and understanding related imaging patterns, experts explained recently.
The effort is fueled by a $1.2 million grant from the Gordon and Betty Moore Foundation, with participation from big names including Johns Hopkins University.
Currently, no unified guidelines exist for assessing tumor response in HCC patients, which can lead to excess costs from redundant imaging and ineffective therapies.
A full-service practice might see a 4.24% decrease in the professional component of reimbursement and a 1.78% drop on the global side, according to a new analysis.